Compare NTGR & CTNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | NTGR | CTNM |
|---|---|---|
| Founded | 1996 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | |
| Sector | Utilities | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 672.3M | 550.7M |
| IPO Year | 2000 | 2024 |
| Metric | NTGR | CTNM |
|---|---|---|
| Price | $24.15 | $15.93 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 4 |
| Target Price | ★ $39.00 | $19.00 |
| AVG Volume (30 Days) | ★ 352.9K | 249.7K |
| Earning Date | 04-29-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 0.46 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $8.64 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $19.00 | $5.71 |
| 52 Week High | $36.86 | $16.91 |
| Indicator | NTGR | CTNM |
|---|---|---|
| Relative Strength Index (RSI) | 51.79 | 60.62 |
| Support Level | $20.36 | $11.73 |
| Resistance Level | $25.33 | $16.91 |
| Average True Range (ATR) | 1.09 | 1.07 |
| MACD | 0.06 | 0.09 |
| Stochastic Oscillator | 54.85 | 85.02 |
Netgear Inc provider of networking technologies for businesses, homes, and service providers. It delivers a wide range of intelligent solutions designed to unleash the full potential of connectivity. The group has two segments: Enterprise and Consumer which offers reliable, easy-to-use, high-performance networking solutions, including switches, routers, access points, software, and AV over IP technologies, tailored to meet the diverse needs of organizations of all sizes. The Home Networking and Mobile offers connectivity, powerful performance, and enhanced security features right out of the box, designed to help keep families safe online, and Others. It conduct business across three geographic territories: Americas; Europe, Middle East and Africa; and Asia Pacific.
Contineum Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of oral small-molecule therapies for neurological, inflammatory, and immunological conditions. The company focuses on developing selective compounds targeting challenging molecular pathways and has built a portfolio of small molecule drug candidates. Its pipeline includes drug candidates in clinical development, such as PIPE-791, an LPA1 receptor antagonist being studied for idiopathic pulmonary fibrosis and chronic pain, and PIPE-307, an M1 receptor inhibitor being evaluated for relapsing-remitting multiple sclerosis and other depressive disorders.